The much loved and talked about Netflix sci-fi series Stranger Things has been turned into a comic series and a few of them have just gone free in Kindle Format on Amazon.

Description
The nostalgia-igniting hit Netflix origina…

Precision Therapeutics Inc. (AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has changed its corporate name to Predictive Oncology Inc., which the Company believes best reflects the company’s mission and strategic focus. In addition to its new corporate name, the Company expects that its common stock will trade under the new Nasdaq ticker symbol of POAI, effective on or about Thursday, June 13, 2019.  Additional information can be found on the company’s website at www.predictiveoncology.net.

Retailers, manufacturers and brands across luxury sectors have had to lay off or furlough employees in response to the loss of income from the COVID-19 healthcare crisis and resultant government-imposed lockdowns.

Predictive Oncology Inc. (AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Amelia Warner, Pharm.D., RPh, as the interim chief operating officer for its Helomics division. Prior to joining Helomics, Dr. Warner founded Global Specimen Solutions, Inc. (GSS) in 2013, which radically improved translational science through powerful new pipeline data management analytics for global specimen data tracking for the pharmaceutical industry.  After rapid market uptake and growth, GSS was sold to a public company in December 2017.  Prior to GSS, Dr. Warner served as CEO for Gentris Corporation, where she led a financial and operational turnaround resulting in the successful sale of Gentris to a public company.  She has also served as head of Clinical Pharmacogenomics and Clinical Specimen Management for Merck Research Laboratories (MRL).  In this role, she led a data overhaul for the Clinical Translational Medicine program, oversaw all clinical pharmacogenomics projects, as well as policies and procedures for biosample collection and storage for clinical trials samples.